Stockreport

ABBV Stock Slides 5%: Is J&J's Icotyde a Threat to Skyrizi? [Yahoo! Finance]

Johnson & Johnson  (JNJ) 
Last johnson & johnson earnings: 4/14 06:31 am Check Earnings Report
US:NYSE Investor Relations: jnj.com
PDF This selloff comes as investors grow wary of Johnson & Johnson 's JNJ newly approved immunology therapy, Icotyde, which could emerge as a competitive threat to Skyrizi, [Read more]